Different susceptibility to 1-methyl-4-phenylpyridium (MPP+)-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B)

Experimental and Toxicologic Pathology

Volumn 65, Issue 1-2, 2013, Pages 153-158

  Ito, Tsuyoshi ^a   Suzuki, Kazuhiko ^a   Uchida, Kazuyuki ^a   Nakayama, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

ALB c mice; C57BL 6 mice; Intracerebroventricular injection; MPP+; MPTP; Strain difference

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; MONOCLONAL ANTIBODY; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BAGG ALBINO MOUSE; BLOOD BRAIN BARRIER; C57BL 6 MOUSE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PERMEABILITY; MOUSE; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; STRAIN DIFFERENCE; SUBSTANTIA NIGRA PARS COMPACTA; TOXICOKINETICS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL DEATH; CORPUS STRIATUM; DISEASE SUSCEPTIBILITY; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MONOAMINE OXIDASE; MPTP POISONING; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

ANIMALIA; MUS;

EID: 84870242894     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2011.07.004     Document Type: Article

References (30)

1. Andersen J.K., Frim D.M., Isacson O., Beal M.F., Breakefield X.O. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res 1994, 656:108-114.
2. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983, 80:4546-4550.
3. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Pert A., Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 1984, 100:189-194.
4. Del Zompo M., Piccardi M.P., Ruiu S., Quartu M., Gessa G.L., Vaccari A. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J Pharmacol 1993, 109:411-414.
5. Filipov N.M., Norwood A.B., Sistrunk S.C. Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. Neuroreport 2009, 20:713-717.
6. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Academic Press, London.
7. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 1991, 257:691-697.
8. Hamre K., Tharp R., Poon K., Xiong X., Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 1999, 828:91-103.
9. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989, 169:59-72.
10. Jossan S.S., Sakurai E., Oreland L. MPTP toxicity in relation to age, dopamine uptake and MAO-B activity in two rodent species. Pharmacol Toxicol 1989, 64:314-318.
11. Kuchroo V.K., Anderson A.C., Waldner H., Munder M., Bettelli E., Nicholson L.B. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002, 20:101-123.
12. Kurkowska-Jastrzebska I., Babiuch M., Joniec I., Przybyłkowski A., Członkowski A., Członkowska A. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol 2002, 2:1213-1218.
13. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984, 292:390-394.
14. Liu Y., Peter D., Roghani A., Schuldiner S., Privé G.G., Eisenberg D., et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
15. Maharaj D.S., Saravanan K.S., Maharaj H., Mohanakumar K.P., Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 2004, 44:355-360.
16. Mitra N., Mohanakumar K.P., Ganguly D.K. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. J Neurochem 1994, 62:1906-1912.
17. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., et al. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol 1994, 126:195-204.
18. Riachi N.J., Harik S.I. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier. Life Sci 1988, 42:2359-2363.
19. Riachi N.J., Harik S.I., Kalaria R.N., Sayre L.M. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J Pharmacol Exp Ther 1988, 244:443-448.
20. Riachi N.J., Dietrich W.D., Harik S.I. Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier. Brain Res 1990, 533:6-14.
21. Sairam K., Saravanan K.S., Banerjee R., Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 2003, 966:245-252.
22. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 2000, 30:171-182.
23. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005, 134:57-66.
24. Stenström A., Sundström E., Fowler C.J. Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Pharmacol Toxicol 1989, 64:276-281.
25. Sundström E., Strömberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 1987, 405:26-38.
26. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
27. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., et al. The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 2008, 204:43-51.
28. Yokoyama H., Kuroiwa H., Yano R., Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008, 29:293-301.
29. Yoshihara S., Ohta S. Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone. Arch Biochem Biophys 1998, 360:93-98.
30. Zimmer J., Geneser F.A. Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP. Neurosci Lett 1987, 78:253-258.